Atlas Trials

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Clinical trial NCT02383212 · COMPLETED

Trial details

NCT number
NCT02383212
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced CancerAdvanced Malignancies
Start date
2015-02-02
Primary completion
2019-11-18
Enrollment
398

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.